Published in J Clin Oncol on May 03, 2004
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21
Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer (2008) 1.11
Applications of nanotechnology in dermatology. J Invest Dermatol (2012) 1.00
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res (2014) 0.94
Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther (2008) 0.91
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma. BMC Cancer (2012) 0.90
Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF. J Carcinog (2007) 0.88
Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One (2012) 0.87
Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mol Cancer (2009) 0.82
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget (2015) 0.80
Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives. World J Gastrointest Oncol (2016) 0.78
Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy. Vaccines (Basel) (2016) 0.78
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. Br J Cancer (2013) 0.77
Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis (2007) 0.76
Targeted therapy in melanoma. Biologics (2009) 0.76
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Mol Cancer (2014) 0.75
Whole body microwave irradiation for improved dacarbazine therapeutical action in cutaneous melanoma mouse model. Radiol Res Pract (2013) 0.75
Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer Metab (2016) 0.75
Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity. Res Pharm Sci (2015) 0.75
The Cytotoxicity of Dacarbazine Potentiated by Sea Cucumber Saponin in Resistant B16F10 Melanoma Cells through Apoptosis Induction. Avicenna J Med Biotechnol (2016) 0.75
Chemotherapy for melanoma: the resultant of conflicting vectors. J Clin Oncol (2004) 0.75
Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. PLoS One (2016) 0.75
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Focus on bladder cancer. Cancer Cell (2004) 2.59
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res (2005) 2.46
Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place (2006) 2.40
Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications. Brain (2002) 2.17
Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol (2004) 2.17
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.99
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Cellular and molecular events leading to the development of skin cancer. Mutat Res (2005) 1.69
The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat (2004) 1.69
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res (2005) 1.66
Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol (2005) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Breast cancer metastasis: challenges and opportunities. Cancer Res (2009) 1.63
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Hepatitis A among international adoptees and their contacts. Clin Infect Dis (2008) 1.60
T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol (2006) 1.59
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis (2004) 1.53
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
Asthma in adventure travelers: a prospective study evaluating the occurrence and risk factors for acute exacerbations. Arch Intern Med (2002) 1.45
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem (2005) 1.38
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther (2007) 1.32
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res (2006) 1.30
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res (2005) 1.30
Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res (2002) 1.30
Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene (2003) 1.30
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol (2008) 1.29
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res (2002) 1.27
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem (2004) 1.24
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs (2007) 1.24
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol (2006) 1.24
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res (2003) 1.23
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res (2004) 1.22
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res (2005) 1.22
Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther (2002) 1.21
alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer (2004) 1.20
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res (2005) 1.20
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem (2009) 1.18
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis (2005) 1.18
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res (2006) 1.17
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 1.17
The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res (2005) 1.16
Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis (2003) 1.15
Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. Cancer Res (2004) 1.15
Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med (2002) 1.14
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res (2008) 1.14
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res (2003) 1.13
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys (2007) 1.13
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res (2003) 1.13
The dicey role of Dicer: implications for RNAi therapy. Cancer Res (2010) 1.13
p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol (2006) 1.13
Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res (2005) 1.12
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Inflammation and melanoma metastasis. Pigment Cell Melanoma Res (2009) 1.11
Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest (2006) 1.11
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res (2007) 1.11
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res (2005) 1.11
Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics (2006) 1.11
Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun (2008) 1.10
Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J Biol Chem (2005) 1.10
Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev (2007) 1.08
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer (2012) 1.08
Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther (2008) 1.08
Chitosan hydrogel for localized gene silencing. Cancer Biol Ther (2011) 1.07
Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother Pharmacol (2006) 1.06
P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol (2008) 1.06
Weight loss and improvement of obesity-related illness in 500 U.S. patients following laparoscopic adjustable gastric banding procedure. Am J Surg (2005) 1.05
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 1.05
A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res (2003) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res (2008) 1.03
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol (2006) 1.02